Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Total Liabilities
Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has total liabilities worth CN¥161.98 Million CNY (≈ $23.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Zhejiang Wolwo Bio-Pharmaceutical Co Ltd generate cash to assess how effectively this company generates cash.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 300357 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TD Power Systems Limited
NSE:TDPOWERSYS
|
India | Rs6.10 Billion |
|
Dalrymple Bay Infrastructure Ltd
AU:DBI
|
Australia | AU$2.51 Billion |
|
Tatung Co
TW:2371
|
Taiwan | NT$75.37 Billion |
|
NCR Atleos Corporation
NYSE:NATL
|
USA | $5.46 Billion |
|
Yangling Metron New Material Co Ltd
SHE:300861
|
China | CN¥668.69 Million |
|
Guanglian Aviation Industry Co Ltd
SHE:300900
|
China | CN¥3.44 Billion |
|
K+S Aktiengesellschaft
F:SDF1
|
Germany | €2.86 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual total liabilities of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥250.30 Million ≈ $36.63 Million |
-3.16% |
| 2023-12-31 | CN¥258.46 Million ≈ $37.82 Million |
+51.36% |
| 2022-12-31 | CN¥170.76 Million ≈ $24.99 Million |
+26.16% |
| 2021-12-31 | CN¥135.36 Million ≈ $19.81 Million |
+76.69% |
| 2020-12-31 | CN¥76.61 Million ≈ $11.21 Million |
+0.47% |
| 2019-12-31 | CN¥76.25 Million ≈ $11.16 Million |
+22.06% |
| 2018-12-31 | CN¥62.47 Million ≈ $9.14 Million |
+32.77% |
| 2017-12-31 | CN¥47.05 Million ≈ $6.89 Million |
+13.88% |
| 2016-12-31 | CN¥41.32 Million ≈ $6.05 Million |
+44.60% |
| 2015-12-31 | CN¥28.57 Million ≈ $4.18 Million |
+60.95% |
| 2014-12-31 | CN¥17.75 Million ≈ $2.60 Million |
+47.51% |
| 2013-12-31 | CN¥12.04 Million ≈ $1.76 Million |
+23.65% |
| 2012-12-31 | CN¥9.73 Million ≈ $1.42 Million |
-50.29% |
| 2011-12-31 | CN¥19.58 Million ≈ $2.87 Million |
-2.49% |
| 2010-12-31 | CN¥20.08 Million ≈ $2.94 Million |
+111.50% |
| 2009-12-31 | CN¥9.49 Million ≈ $1.39 Million |
-- |
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more